Polycythemia vera (PV) is a chronic myeloproliferative disorder whose major morbidity and mortality are thrombohaemorragic events and progression to acute leukaemia or myelofibrosis. Whether the haematocrit and platelet count predict such complications remains unclear. The European Collaboration on Low-dose Aspirin in Polycythemia Vera prospective study included 1638 PV patients. A total of 164 deaths (10%), 145 (8.85%) major thrombosis and 226 (13.8%) total thrombosis were encountered during 4393 person-years follow-up (median 2.8 years). In time-dependent multivariable analysis, a haematocrit in the evaluable range of 40-55% was neither associated with the occurrence of thrombotic events, mortality nor with haematological progression in the studied population. The haematocrit of patients in the highest and lowest deciles at baseline was maintained within a narrow interval of haematocrit values ranging from 40% to 47% throughout follow-up. High platelet count was associated with a lower progression rate to acute leukaemia/myelofibrosis, whereas it had no significant relationship with thrombotic events or mortality. Our findings do not suggest that the range of haematocrit (<55%) and platelet counts (<600 x 10(9)/l) we encountered in our population had an impact on the outcome of PV patients treated by current therapeutic strategies.

The haematocrit and platelet target in polycythemia vera / Di Nisio, M; Barbui, T; Di Gennaro, L; Borrelli, G; Finazzi, G; Landolfi, R; Leone, G; Marfisi, R; Porreca, E; Ruggeri, M; Rutjes, A; Tognoni, G; Vannucchi, Am; Marchioli, R; European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP), Investigators. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 136:2(2007), pp. 249-259. [10.1111/j.1365-2141.2006.06430.x]

The haematocrit and platelet target in polycythemia vera

Rutjes A;
2007

Abstract

Polycythemia vera (PV) is a chronic myeloproliferative disorder whose major morbidity and mortality are thrombohaemorragic events and progression to acute leukaemia or myelofibrosis. Whether the haematocrit and platelet count predict such complications remains unclear. The European Collaboration on Low-dose Aspirin in Polycythemia Vera prospective study included 1638 PV patients. A total of 164 deaths (10%), 145 (8.85%) major thrombosis and 226 (13.8%) total thrombosis were encountered during 4393 person-years follow-up (median 2.8 years). In time-dependent multivariable analysis, a haematocrit in the evaluable range of 40-55% was neither associated with the occurrence of thrombotic events, mortality nor with haematological progression in the studied population. The haematocrit of patients in the highest and lowest deciles at baseline was maintained within a narrow interval of haematocrit values ranging from 40% to 47% throughout follow-up. High platelet count was associated with a lower progression rate to acute leukaemia/myelofibrosis, whereas it had no significant relationship with thrombotic events or mortality. Our findings do not suggest that the range of haematocrit (<55%) and platelet counts (<600 x 10(9)/l) we encountered in our population had an impact on the outcome of PV patients treated by current therapeutic strategies.
2007
136
2
249
259
The haematocrit and platelet target in polycythemia vera / Di Nisio, M; Barbui, T; Di Gennaro, L; Borrelli, G; Finazzi, G; Landolfi, R; Leone, G; Marfisi, R; Porreca, E; Ruggeri, M; Rutjes, A; Tognoni, G; Vannucchi, Am; Marchioli, R; European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP), Investigators. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 136:2(2007), pp. 249-259. [10.1111/j.1365-2141.2006.06430.x]
Di Nisio, M; Barbui, T; Di Gennaro, L; Borrelli, G; Finazzi, G; Landolfi, R; Leone, G; Marfisi, R; Porreca, E; Ruggeri, M; Rutjes, A; Tognoni, G; Vann...espandi
File in questo prodotto:
File Dimensione Formato  
2007_DiNisio Haematocrit ECLAP BJH.pdf

Open access

Descrizione: Author's pesonal copy
Tipologia: Versione pubblicata dall'editore
Dimensione 603.41 kB
Formato Adobe PDF
603.41 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1286661
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 151
  • ???jsp.display-item.citation.isi??? 134
social impact